Literature DB >> 11197217

Anti-apoptotic role of Bfl-1 in staurosporine-treated B-lymphoblastic cells.

Y H Shim1, E K Byun, M J Lee, J Huh, C W Kim.   

Abstract

To examine the relationship between the expression level of Bfl-1 and the susceptibility to staurosporine-induced apoptosis in B-lymphoblastic cells, we tested cell survival in 4 cell lines: 2 that are Bfl-1-nonexpressing (Reh and JM-1) and 2 that are Bfl-1-expressing (IM-9 and Wil2-NS). Reh and JM-1 showed apoptosis levels of 62% (Reh) and 30% (JM-1) as early as 3 hours after treatment with staurosporine, whereas IM-9 and Wil2-NS showed apoptosis levels of only 40% and 26%, respectively, even after 1 day of treatment with staurosporine. Either induced expression of Bfl-1 with 12-o-tetradecanoyl phorbol-13-acetate or exogenous expression of Bfl-1 by transfection in Reh cells promoted cell survival. These results suggest that expression of Bfl-1 contributes to regulating apoptosis in the B-cell lines we examined.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11197217

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  4 in total

Review 1.  BCL2A1: the underdog in the BCL2 family.

Authors:  M Vogler
Journal:  Cell Death Differ       Date:  2011-11-11       Impact factor: 15.828

2.  Kruppel-like factor 7 overexpression suppresses hematopoietic stem and progenitor cell function.

Authors:  Laura G Schuettpelz; Priya K Gopalan; Felipe O Giuste; Molly P Romine; Ronald van Os; Daniel C Link
Journal:  Blood       Date:  2012-08-30       Impact factor: 22.113

3.  Targeting Bfl-1 via acute CDK9 inhibition overcomes intrinsic BH3-mimetic resistance in lymphomas.

Authors:  Scott Boiko; Theresa Proia; Maryann San Martin; Gareth P Gregory; Michelle Min Wu; Neeraj Aryal; Maureen Hattersley; Wenlin Shao; Jamal C Saeh; Stephen E Fawell; Ricky W Johnstone; Lisa Drew; Justin Cidado
Journal:  Blood       Date:  2021-05-27       Impact factor: 22.113

4.  Up-regulation of anti-apoptotic genes confers resistance to the novel anti-leukaemic compound PEP005 in primary AML cells.

Authors:  Peter Hampson; Keqing Wang; Elisabeth Ersvær; Emmet McCormack; Julia Schüler; Heinz-Herbert Fiebig; Bjørn Tore Gjertsen; Øystein Bruserud; Janet M Lord
Journal:  Oncoscience       Date:  2014-08-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.